Home health remedies Thermo Fisher expands biologics manufacturing at 3 sites

Thermo Fisher expands biologics manufacturing at 3 sites

57
0
SHARE

With biopharmaceuticals dominating the drug development landscape, Thermo Fisher Scientific says it needs more capacity throughout its manufacturing network. To that end, its CDMO operations will invest $150 million in three sites.

The company says the investments will provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing at sites in Greenville, North Carolina, as well as Monza and Ferentino, Italy. Each site will get aseptic filling lines and isolator technology. Construction is slated to be complete within 24 months.

“These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise,” Michel Lagarde, president of Thermo Fisher pharma services, said in an statement this week.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The Waltham, Massachusetts-based pharma services company jumped into the contract manufacturing business big-time two years ago with its $7.2 billion deal to buy Patheon, one of the largest contract manufacturers in the world.

RELATED: Patheon buyout complete as 2 deals and $12.7B transform CDMO industry

In fact, 2017 turned into a watershed year for the CDMO industry. Lonza paid $5.5 billion for Capsugel to get a solid place in that niche of the business, then followed that up with a small deal for Netherlands-based PharmaCell, a gene and cell contract manufacturer in Europe.

But the consolidation didn’t stop there. Weeks after those two deals were done, Catalent, another sizable operator, agreed to pay $950 million to buy Cook Pharmica to get its extensive biologics manufacturing operation in Bloomington, Indiana.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here